We are live on
!
Find out more
Lyell Immunopharma
LYEL
LYEL
62 hedge funds and large institutions have $1.22B invested in Lyell Immunopharma in 2021 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
56% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 18
19% more funds holding
Funds holding: 52 → 62 (+10)
0.08% more ownership
Funds ownership: 1.64% → 1.72% (+0.08%)
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
6% less capital invested
Capital invested by funds: $1.29B → $1.22B (-$72.7M)
25% less funds holding in top 10
Funds holding in top 10: 8 → 6 (-2)
Holders
62
Holders Change
+10
Holders Change %
+19.23%
% of All Funds
1.09%
Holding in Top 10
6
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-25%
% of All Funds
0.11%
New
28
Increased
11
Reduced
11
Closed
18
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
BlackRock
New York
|
+$17.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$17.4M |
| 3 |
HH
HSG Holding
Na,
Hong Kong
|
+$9.13M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.94M |
| 5 |
Brown Advisory
Baltimore,
Maryland
|
+$6.84M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$16.6M |
| 2 |
ACA
Arena Capital Advisors
Los Angeles,
California
|
-$8.85M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$4.4M |
| 4 |
Goldman Sachs
New York
|
-$3.28M |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$2.6M |
